NCT02376985View on ClinicalTrials.gov

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

October 16, 2018

Conditions
Breast Cancer
Interventions
PROCEDURE

Oral management

DRUG

Everolimus

Trial Locations (1)

259-1193

Tokai University, School of Medicine, Isehara

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Comprehensive Support Project for Oncology Research

OTHER